Effect of the rho-associated kinase inhibitor eye drop (Ripasudil) on corneal endothelial wound healing

Investigative Ophthalmology and Visual Science

Volumn 57, Issue 3, 2016, Pages 1284-1292

  Okumura, Naoki ^a   Okazaki, Yugo ^a   Inoue, Ryota ^a   Kakutani, Kazuya ^a   Nakano, Shinichiro ^a   Kinoshita, Shigeru ^b   Koizumi, Noriko ^a  

^a DOSHISHA UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Bullous keratopathy; Corneal endothelial cells; Rho kinase inhibitor

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); KI 67 ANTIGEN; NERVE CELL ADHESION MOLECULE; RHO KINASE; RIPASUDIL; EYE DROPS; ISOQUINOLINE DERIVATIVE; K-115; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMICROSCOPY; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL REGENERATION; CENTRAL CORNEAL THICKNESS; CONTROLLED STUDY; CORNEA ENDOTHELIUM; CORNEA OPACITY; CORNEAL ENDOTHELIAL CELL LOSS; CORNEAL PACHYMETRY; DISEASE ASSESSMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SLIT LAMP MICROSCOPY; WOUND HEALING; ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CORNEAL INJURIES; DISEASE MODEL; DRUG EFFECTS; INJURIES; PATHOLOGY;

ADULT; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CORNEAL INJURIES; DISEASE MODELS, ANIMAL; ENDOTHELIUM, CORNEAL; HUMANS; IMMUNOHISTOCHEMISTRY; ISOQUINOLINES; OPHTHALMIC SOLUTIONS; RABBITS; RHO-ASSOCIATED KINASES; SULFONAMIDES; WOUND HEALING;

EID: 84961641140     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-18586     Document Type: Article

References (45)

1. Tan DT, Dart JK, Holland EJ, Kinoshita S. Corneal transplantation. Lancet. 2012;379:1749-1761.
2. Okumura N, Ueno M, Koizumi N, et al. Enhancement on primate corneal endothelial cell survival in vitro by a ROCK inhibitor. Invest Ophthalmol Vis Sci. 2009;50:3680-3687.
3. Okumura N, Koizumi N, Ueno M, et al. Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops. Br J Ophthalmol. 2011;95:1006-1009.
4. Okumura N, Koizumi N, Kay EP, et al. The ROCK inhibitor eye drop accelerates corneal endothelium wound healing. Invest Ophthalmol Vis Sci. 2013;54:2493-2502.
5. Koizumi N, Okumura N, Ueno M, Nakagawa H, Hamuro J, Kinoshita S. Rho-associated kinase inhibitor eye drop treatment as a possible medical treatment for fuchs corneal dystrophy. Cornea. 2013;32:1167-1170.
6. Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137-144.
7. Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48:3216-3222.
8. Williams R D, Novack G D, van Haarlem T, Kopczynski C. Group ARPAS. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011;152:834-841.
9. Inoue T, Tanihara H. Rho-associated kinase inhibitors: a novel glaucoma therapy. Prog Retin Eye Res. 2013;37:12.
10. Van de Velde S, Van Bergen T, Sijnave D, et al. AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014;55: 1006-1016.
11. Tanihara H, Inoue T, Yamamoto T, et al. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131:1288-1295.
12. Tanihara H, Inoue T, Yamamoto T, et al. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156:731-736.
13. Tanihara H, Inoue T, Yamamoto T, et al. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015;93:e254-260.
14. Garnock-Jones KP. Ripasudil: first global approval. Drugs. 2014;74:2211-2215.
15. Isobe T, Mizuno K, Kaneko Y, Ohta M, Koide T, Tanabe S. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res. 2014;39:813-822.
16. Jin G, Wong ST. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today. 2014;19:637-644.
17. Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens MH. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today. 2015;20:1027-1034.
18. Wurth R, Thellung S, Bajetto A, Mazzanti M, Florio T, Barbieri F. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds. Drug Discov Today. 2016;21:190-199.
19. Okumura N, Kusakabe A, Hirano H, et al. Density-gradient centrifugation enables the purification of cultured corneal endothelial cells for cell therapy by eliminating senescent cells. Sci Rep. 2015;5:15005.
20. Nakahara M, Okumura N, Kay EP, et al. Corneal endothelial expansion promoted by human bone marrow mesenchymal stem cell-derived conditioned medium. PLoS One. 2013;8: e69009.
21. Matsubara M, Tanishima T. Wound-healing of the corneal endothelium in the monkey: a morphometric study. Jpn J Ophthalmol. 1982;26:264-273.
22. Matsubara M, Tanishima T. Wound-healing of corneal endothelium in monkey: an autoradiographic study. Jpn J Ophthalmol. 1983;27:444-450.
23. Al-Yousuf N, Mavrikakis I, Mavrikakis E, Daya SM. Penetrating keratoplasty: indications over a 10 year period. Br J Ophthalmol. 2004;88:998-1001.
24. Ghosheh FR, Cremona FA, Rapuano CJ, et al. Trends in penetrating keratoplasty in the United States 1980-2005. Int Ophthalmol. 2008;28:147-153.
25. Keenan TD, Jones MN, Rushton S, et al. Trends in the indications for corneal graft surgery in the United Kingdom: 1999 through 2009. Arch Ophthalmol. 2012;130:621-628.
26. Eye Bank Association of America. Eye Banking Statistical Report. Washington, DC; 2013.
27. Dandona L, Naduvilath TJ, Janarthanan M, Ragu K, Rao GN. Survival analysis and visual outcome in a large series of corneal transplants in India. Br J Ophthalmol. 1997;81:726-731.
28. Shimazaki J, Amano S, Uno T, Maeda N, Yokoi N. National survey on bullous keratopathy in Japan. Cornea. 2007;26:274-278.
29. Tan DT, Janardhanan P, Zhou H, et al. Penetrating keratoplasty in Asian eyes: the Singapore Corneal Transplant Study. Ophthalmology. 2008;115:975-982.
30. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96:614-618.
31. Joyce NC. Proliferative capacity of the corneal endothelium. Prog Retin Eye Res. 2003;22:359-389.
32. Bourne WM. Clinical estimation of corneal endothelial pump function. Trans Am Ophthalmol Soc. 1998;96:229-239.discussion 239-242.
33. Hoppenreijs VP, Pels E, Vrensen GF, Oosting J, Treffers WF. Effects of human epidermal growth factor on endothelial wound healing of human corneas. Invest Ophthalmol Vis Sci. 1992;33:1946-1957.
34. Hoppenreijs VP, Pels E, Vrensen GF, Treffers WF. Effects of platelet-derived growth factor on endothelial wound healing of human corneas. Invest Ophthalmol Vis Sci. 1994;35:150-161.
35. Lu J, Lu Z, Reinach P, et al. TGF-beta2 inhibits AKT activation and FGF-2-induced corneal endothelial cell proliferation. Exp Cell Res. 2006;312:3631-3640.
36. Okumura N, Inoue R, Okazaki Y, et al. Effect of the Rho kinase inhibitor Y-27632 on corneal endothelial wound healing. Invest Ophthalmol Vis Sci. 2015;56:6067-6074.
37. Naumann GO, Schlotzer-Schrehardt U. Keratopathy in pseu-doexfoliation syndrome as a cause of corneal endothelial decompensation: a clinicopathologic study. Ophthalmology. 2000;107:1111-1124.
38. Kawaguchi R, Saika S, Wakayama M, Ooshima A, Ohnishi Y, Yabe H. Extracellular matrix components in a case of retrocorneal membrane associated with syphilitic interstitial keratitis. Cornea. 2001;20:100-103.
39. Lee HT, Lee JG, Na M, Kay EP. FGF-2 induced by interleukin-1 beta through the action of phosphatidylinositol 3-kinase mediates endothelial mesenchymal transformation in corneal endothelial cells. J Biol Chem. 2004;279:32325-32332.
40. Okumura N, Kay EP, Nakahara M, Hamuro J, Kinoshita S, Koizumi N. Inhibition of TGF-beta signaling enables human corneal endothelial cell expansion in vitro for use in regenerative medicine. PLoS One. 2013;8:e58000.
41. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007;50:17-24.
42. Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol. 2008;20:242-248.
43. Hu E, Lee D. Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges. Expert Opin Ther Targets. 2005;9:715-736.
44. Nakagawa H, Koizumi N, Okumura N, Suganami H, Kinoshita S. Morphological changes of human corneal endothelial cells after rho-associated kinase inhibitor eye drop (ripasudil) administration: a prospective open-label clinical study. PLoS One. 2015;10:e0136802.
45. Okumura N, Okazaki Y, Inoue R, et al. Rho-associated kinase inhibitor eye drop (ripasudil) transiently alters the morphology of corneal endothelial cells. Invest Ophthalmol Vis Sci. 2015;56:7560-7567.